US 9,808,462 B2
Modulators of androgen synthesis
Suzanne Dilly, Oxfordshire (GB); Gregory Stoloff, London (GB); and Paul Taylor, London (GB)
Assigned to Tangent Reprofiling Limited, London (GB)
Filed by Tangent Reprofiling Limited, London (GB)
Filed on Feb. 27, 2017, as Appl. No. 15/444,066.
Application 14/723,225 is a division of application No. 14/037,481, filed on Sep. 26, 2013, granted, now 9,072,743, issued on Jul. 7, 2015.
Application 15/444,066 is a continuation of application No. 14/723,225, filed on May 27, 2015, granted, now 9,585,887.
Claims priority of provisional application 61/871,662, filed on Aug. 29, 2013.
Claims priority of provisional application 61/705,790, filed on Sep. 26, 2012.
Prior Publication US 2017/0189407 A1, Jul. 6, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/517 (2006.01); A61K 31/42 (2006.01); A61K 31/20 (2006.01); A61K 31/519 (2006.01); A61K 31/201 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/201 (2013.01)] 20 Claims
 
1. A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual a therapeutically effective amount of risperidone and from 0.01 mg/kg/day to 0.5 mg/kg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid.